

Supplemental Tables

Cell line	D5		D13		D7		D16		vWA		TH01		TPOX		CSF1		Amel	
	D5'		D13'		D7'		D16'		vWA'		TH01'		TPOX'		CSF1'		Amel'	
Capan1	11	11	9	9	10	11	13	14	16	16	6	6	8	11	11	11	X	X
Capan2	11	12	11	12	9	11	9	13	17	17	9,3	9,3	8	8	11	12	X	X
DanG	12	13	8	8	10	13	8	11	16	18	9,3	9,3	10	10	13	13	X	X
FamPAC	10	11	8	8	11	11	14	14	15	15	9	9	8	8	10	10	X	X
L3.6pl (COLO357)	11	11	8	8	8	10	9	12	18	18	7	7	8	8	11	12	X	X
MiaPaca2	12	13	12	13	12	13	10	13	15	15	9	10	9	9	10	10	X	X
Panc1	11	13	11	11	8	10	11	11	15	15	7	8	8	11	10	12	X	X
PaTu8988T	11	13	12	13	7	8	11	12	16	16	6	6	8	11	11	13	X	X
Suit2 (subclone 007)	11	12	9	11	9	11	9	9	17	17	6	6	8	10	11	12	X	X
A427	12	12	11	12	8	12	11	13	17	17	9	9	8	11	10	12	X	Y
A549	11	11	11	11	8	11	11	12	14	14	8	9	8	11	10	12	X	Y
CALU6	11	11	11	11	10	10	13	13	17	17	9	9	8	8	12	12	X	X
COLO699	11	12	11	11	11	13	12	12	17	17	9	9	8	8	10	10	X	X
ETCC016	11	12	10	10	9	12	12	12	17	19	9	9	8	11	10	12	X	X
HCC44	11	13	11	11	8	10	9	13	15	15	9	9	8	12	9	11	X	X
HCC78	11	12	8	12	9	9	11	13	15	18	7	9	8	11	11	12	X	Y
HCC827	12	12	9	9	11	12	12	12	18	18	6	6	8	8	11	11	X	X
LXF289	9	10	9	11	10	10	13	13	17	18	6	9	11	11	12	13	X	Y
SKLU1	11	11	10	10	9	9	8	8	16	17	7	7	8	10	10	10	X	X
A172	11	12	11	11	11	11	12	12	20	20	6	9,3	8	11	9	12	X	Y
LN18	11	13	12	13	8	10	11	13	17	18	9	9	8	8	12	12	X	Y
LN229	11	12	10	11	8	11	12	12	16	19	9,3	9,3	8	8	12	12	X	X
T98G	10	12	13	13	9	10	13	13	17	20	7	9,3	8	8	10	12	X	Y
U87	11	12	8	11	8	9	12	12	15	17	9,3	9,3	8	8	10	11	X	X
U138	11	11	9	11	9	9	12	13	18	18	6	6	8	8	12	12	X	Y
U251	11	12	10	11	10	12	12	12	16	18	9,3	9,3	8	8	11	12	X	Y
Cal27	11	12	10	11	10	10	11	12	14	17	6	9,3	8	8	10	12	X	X
Cal33	11	12	8	13	8	10	11	11	17	17	9	9	8	8	11	12	X	Y
UDSCC2	10	11	8	8	8	9	11	13	15	18	8	9	8	10	11	12	X	Y
UMSCC1	10	13	8	11	9	12	12	13	15	18	6	6	8	11	10	12	X	X
UPCISCC040	10	11	8	12	9	10	11	11	17	18	6	8	11	11	12	12	X	Y
UPCISCC099	11	12	8	13	7	9 / 10	11	12	14	18 / 19	6	9	11	11	11	12	X	X
UPCISCC131	11	11	11	13	11	12	13	13	15	17	7	9	11	11	12	12	X	Y
UPCISCC154	11	12	9	12	9	10	13	13	17	17	7	7	8	9	10	12	X	Y
UTSCC16A	12	14	9	12	9	11	11	11	19	19	9	9	9	9	10	11	X	X
93-VU-147T	11	12	12	12	10	11	9	11	18	18	7	9	9	11	11	12	X	X
BT20	12	12	11	11	10	10	11	14	16	17	7	9,3	11	11	12	12	X	X
BT474	11	13	11	11	9	12	9	11	15	16	7	7	8	8	10	11	X	X
BT549	11	11	11	11	9	10	8	8	15	15	9,3	9,3	8	8	10	12	X	X
EFM19	11	11	8	12	9	9	11	12	14	14	7	8	8	12	9	9	X	X
HCC1806	13	13	11	11	10	12	10	10	16	18	8	8	8	9	12	12	X	X
HCC1937	12	12	13	13	9	10	13	14	16	17	6	6	11	11	12	12	X	X

MCF7	12	12	11	11	8	9	11	12	14	15	6	6	9	12	10	10	X	X
MDA-MB231	12	12	13	13	8	9	12	12	15	18	7	9,3	8	9	12	13	X	X
MDA-MB436	13	13	10	10	10	10	9	9	14	20	9,3	9,3	8	8	12	12	X	X
MDA-MB453	11	11	12	12	10	10	9	9	17	18	6	6	10	10	10	12	X	X
MDA-MB468	12	12	12	12	8	8	9	9	18	18	7	7	8	9	12	12	X	X
SKBR3	9	12	11	12	9	12	9	9	17	17	8	9	8	11	12	12	X	X
T47D	12	12	12	12	11	11	10	10	14	14	6	6	11	11	11	13	X	X
ZR75-1	13	13	9	9	10	11	11	11	16	18	7	9,3	8	8	10	11	X	X

Supplementary Table 1: Short tandem repeat profiling of cell lines used in this study (Service provided by DSMZ, Braunschweig).

Cell line	Tumor type	Culture medium and supplements	CO ₂ [vol%]
Capan1	Pancreatic cancer	RPMI-1640 + 10% FCS + 10 mM HEPES + P/S	5
Capan2	Pancreatic cancer	DMEM + 10% FCS + P/S	7.5
DanG	Pancreatic cancer	RPMI-1640 + 10% FCS + 10 mM HEPES + P/S	5
FamPAC	Pancreatic cancer	RPMI-1640 + 10% FCS + 10 mM HEPES + P/S	5
L3.6pl (COLO357)	Pancreatic cancer	DMEM + 10% FCS + P/S	7.5
MiaPaca2	Pancreatic cancer	DMEM + 10% FCS + P/S	7.5
Panc1	Pancreatic cancer	DMEM + 10% FCS + P/S	7.5
PaTu8988T	Pancreatic cancer	DMEM + 10% FCS + P/S	7.5
Suit2 (subclone 007)	Pancreatic cancer	DMEM + 10% FCS + P/S	7.5
A427	Lung adenocarcinoma	RPMI-1640 + 10% FCS + 10 mM HEPES + P/S	5
A549	Lung adenocarcinoma	DMEM + 10% FCS + P/S	7.5
CALU6	Lung adenocarcinoma	MEM (+ Earle's salts), 10% FCS + P/S	5
COLO699	Lung adenocarcinoma	RPMI-1640 + 10% FCS + 10 mM HEPES + P/S	5
ETCC016	Lung adenocarcinoma	DMEM + 10% FCS + P/S	7.5
HCC44	Lung adenocarcinoma	RPMI-1640 + 10% FCS + 10 mM HEPES + P/S	5
HCC78	Lung adenocarcinoma	RPMI-1640 + 10% FCS + 10 mM HEPES + P/S	5
HCC827	Lung adenocarcinoma	RPMI-1640 + 15% FCS + 10 mM HEPES + P/S	5
LXF289	Lung adenocarcinoma	Ham's F10 + 10% FCS + P/S	5
SKLU1	Lung adenocarcinoma	EMEM + 10% FCS, + P/S	5
A172	Glioblastoma	DMEM + 10% FCS + P/S	7.5
LN18	Glioblastoma	DMEM + 10% FCS + P/S	7.5
LN229	Glioblastoma	DMEM + 10% FCS + P/S	7.5
T98G	Glioblastoma	DMEM + 10% FCS + P/S	7.5
U87	Glioblastoma	DMEM + 10% FCS + P/S	7.5
U138	Glioblastoma	DMEM + 10% FCS + P/S	7.5
U251	Glioblastoma	DMEM + 10% FCS + P/S	7.5
Cal27	Head and neck cancer	DMEM + 10% FCS + P/S	7.5
Cal33	Head and neck cancer	DMEM + 10% FCS + P/S	7.5
UDSCC2	Head and neck cancer	DMEM + 10% FCS + P/S	7.5
UMSCC1	Head and neck cancer	DMEM + 10% FCS + P/S	7.5

UPCISCC040	Head and neck cancer	DMEM + 10% FCS + P/S	7.5
UPCISCC099	Head and neck cancer	DMEM + 10% FCS + P/S	7.5
UPCISCC131	Head and neck cancer	DMEM + 10% FCS + P/S	7.5
UPCISCC154	Head and neck cancer	DMEM + 10% FCS + P/S	7.5
UTSCC16A	Head and neck cancer	DMEM + 10% FCS + P/S	7.5
93-VU-147T	Head and neck cancer	DMEM + 10% FCS + P/S	7.5
BT20	Breast cancer	DMEM/F12 (1 + 1) + 10% FCS + P/S	7.5
BT474	Breast cancer	RPME-1640 + 10% FCS + 10 mM HEPES + P/S	5
BT549	Breast cancer	DMEM + 10% FCS + P/S	7.5
EFM19	Breast cancer	RPME-1640 + 10% FCS + 10 mM HEPES + P/S	5
HCC1806	Breast cancer	RPME-1640 + 10% FCS + 10 mM HEPES + P/S	5
HCC1937	Breast cancer	RPME-1640 + 10% FCS + 10 mM HEPES + P/S	5
MCF7	Breast cancer	RPME-1640 + 10% FCS + 10 mM HEPES + P/S	5
MDA-MB231	Breast cancer	DMEM + 10% FCS + P/S	7.5
MDA-MB436	Breast cancer	DMEM/F12 (1 + 1) + 10% FCS + P/S	7.5
MDA-MB453	Breast cancer	DMEM + 10% FCS + P/S	7.5
MDA-MB468	Breast cancer	DMEM/F12 (1 + 1) + 10% FCS + P/S	7.5
SKBR3	Breast cancer	DMEM + 10% FCS + P/S	7.5
T47D	Breast cancer	RPME-1640 + 10% FCS + 10 mM HEPES + P/S	5
ZR75-1	Breast cancer	RPME-1640 + 10% FCS + 10 mM HEPES + P/S	5

Supplementary Table 2: Overview on cell lines and culture media used in this study. FCS (fetal calf serum), P/S (100 U/ml penicillin and 0.1 mg/ml streptomycin).